- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06388083
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease (DRAGON II)
April 26, 2024 updated by: Belite Bio, Inc
A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study will be comprised of a Phase 1b part conducted in Japan and a Phase 2/3 part.
The Phase 1b part of the study will be open-label and will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of daily doses of 5 mg tinlarebant, administered for 7 days, in Japanese subjects with Stargardt Disease (STGD1).
The Phase 2/3 part of the study will be randomized, double masked, and placebo controlled to evaluate the safety, tolerability, and efficacy of daily doses of 5 mg tinlarebant, administered for 24 months, in subjects with STGD1.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Belite Bio Clinical Operations
- Phone Number: +886 972 080 097
- Email: clinicaltrial@belitebio.com
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75231
- Belite Study Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects must have clinically diagnosed STGD1 with at least one mutation identified in the ABCA4 gene.
- Subjects must have a defined aggregate atrophic lesion in 1 or both eyes.
- Minimum BCVA is required in the study eye
Exclusion Criteria:
- Any ocular disease other than STGD1 that, in the opinion of the investigator, would complicate assessment of a treatment effect.
- History of ocular surgery in the study eye in the last 3 months.
- Any prior gene therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LBS-008, Tinlarebant
5 mg tablet taken orally once a day
|
5 mg tablet
Other Names:
|
Placebo Comparator: Placebo
Placebo tablets for tinlarebant 5 mg prepared similarly
|
Placebo tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the annualized rate of change from baseline lesion size in aggregate area of atrophy
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the annualized rate of change in total area of atrophy
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
Change in BCVA measured by the ETDRS method
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
July 1, 2027
Study Registration Dates
First Submitted
April 23, 2024
First Submitted That Met QC Criteria
April 26, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 26, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LBS-008-CT07
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stargardt Disease 1
-
Institute of Molecular and Clinical Ophthalmology...RecruitingStargardt Disease | Stargardt Disease 1 | Fundus Flavimaculatus | Macular Degeneration, Stargardt | Macular Dystrophy With Flecks, Type 1Switzerland
-
Alkeus Pharmaceuticals, Inc.RecruitingStargardt Disease | Stargardt Macular Degeneration | Stargardt Macular Dystrophy | Autosomal Recessive Stargardt Disease 1 (ABCA4-related)United States
-
Alkeus Pharmaceuticals, Inc.Enrolling by invitationStargardt Disease | Stargardt Macular Degeneration | Stargardt Macular Dystrophy | Autosomal Recessive Stargardt Disease 1 (ABCA4-related)United States
-
West China HospitalActive, not recruiting
-
Belite Bio, IncActive, not recruitingStargardt Disease 1United States, Australia, Belgium, China, France, Germany, Hong Kong, Netherlands, Switzerland, Taiwan, United Kingdom
-
Stargazer Pharmaceuticals, Inc.Completed
-
Ophthalmos Research and Education InstituteCompletedStargardt Disease 1 | Dry AMDFrance, Germany, Italy
-
Pomeranian Medical University SzczecinUnknownRetinal Degeneration | Retinitis Pigmentosa | Age Related Macular Degeneration | Stargardt Disease 1Poland
-
Queen's University, BelfastUniversity of SussexUnknownRetinitis Pigmentosa | Low Vision | Albinism | Stargardt Disease 1 | Stargardt Disease 3 | Stargardt Disease 4United Kingdom
-
Barcelona Macula FoundationRecruitingRetinitis Pigmentosa | Choroideremia | Stargardt Disease 1 | Best Disease | Pattern Dystrophy of MaculaSpain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States